

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Study did not use antibodies.	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Study did not use cells.	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Study did not use cells.	
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Study did not use animals.	
Animal observed in or captured from the field: Provide species, sex and age where possible	Study did not use animals.	
Model organisms: Provide Accession number in repository (where relevant) OR RRID	Study did not use animals.	
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Study did not use plants.	
Microbes: provide species and strain, unique accession number if available, and source	Study did not use plants.	
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods/paragraph8	
Provide statement confirming informed consent obtained from study participants.	Methods/paragraph8	
Report on age and sex for all study participants.	Table1	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	N/A. The 12 trial registration numbers involved in the study were: CTR20190971/CTR20191332/CTR20190949/CTR20191365/CTR20191688/CTR20191799/CTR20191398/CTR20191847/CTR20200801/CTR20200197/CTR20200098/CTR20200576.	√
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	No step-by-step protocols	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Methods/paragraph1	
Randomisation	No Randomisation	
Blinding	No Blinding	
Inclusion/exclusion criteria	Methods/paragraph3-4	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	N/A. About five times	√
Define whether data describe technical or biological replicates	Methods/paragraph8-9	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods/paragraph8	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Study did not use animals.	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Study did not involved specimen and field samples.	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Methods/paragraph8	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Methods/paragraph8	
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Methods/paragraph9	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	N/A. We provide protocols for access or restriction on access in Data Sharing Statement.	√
If data are publicly available, provide accession number in repository or DOI or URL.	N/A. We provide the address to obtain the shared data in Data Sharing Statement.	√
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	N/A. Study did not reuse publicly available data.	√
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	N/A. The statistical software is SPSS 25.0.	√
If code is publicly available, provide accession number in repository, or DOI or URL.	No Code	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: <https://dx.doi.org/10.21037/atm-21-5010>